Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$8.96
-1.5%
$11.19
$8.26
$19.00
$829.31M1.9383,793 shs28,199 shs
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$17.90
-2.6%
$28.50
$16.78
$98.00
$168.06M2.1388,450 shs4,582 shs
Oculis Holding AG stock logo
OCS
Oculis
$19.50
+0.5%
$20.73
$10.55
$23.08
$851.41M0.0176,185 shs3,908 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$21.66
-0.1%
$22.77
$12.17
$26.55
$883.17M0.58178,249 shs10,204 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
+3.41%-11.06%-20.85%-26.99%-48.15%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
+3.49%-16.07%-31.03%-54.05%-79.24%
Oculis Holding AG stock logo
OCS
Oculis
-1.32%-1.22%-6.60%+14.39%+62.89%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
+0.18%-0.60%-1.90%+2.99%+66.00%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
0.2041 of 5 stars
0.00.00.00.03.01.70.0
Korro Bio, Inc. stock logo
KRRO
Korro Bio
1.5054 of 5 stars
3.61.00.00.01.80.00.6
Oculis Holding AG stock logo
OCS
Oculis
1.9889 of 5 stars
3.53.00.00.01.90.00.6
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
3.9534 of 5 stars
0.85.01.71.13.43.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
3.00
BuyN/AN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
3.17
Buy$136.33661.64% Upside
Oculis Holding AG stock logo
OCS
Oculis
3.00
Buy$29.5051.28% Upside
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.50
Reduce$21.00-3.03% Downside

Current Analyst Ratings Breakdown

Latest KRRO, PAHC, GYRE, and OCS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/20/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
3/19/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$105.00 ➝ $95.00
3/13/2025
Oculis Holding AG stock logo
OCS
Oculis
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$37.00 ➝ $41.00
3/13/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/13/2025
Oculis Holding AG stock logo
OCS
Oculis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $29.00
3/11/2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
Noble Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
2/10/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderweight ➝ Underweight$20.00 ➝ $22.00
1/10/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$155.00
1/7/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
1/6/2025
Oculis Holding AG stock logo
OCS
Oculis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$105.76M7.93$0.18 per share50.49$0.18 per share49.77
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$2.27M74.00N/AN/A$21.19 per share0.84
Oculis Holding AG stock logo
OCS
Oculis
$980K868.78N/AN/A$2.87 per share6.79
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$1.11B0.79$1.99 per share10.87$6.09 per share3.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-$92.93M$0.05177.18N/A-84.57%-118.43%-71.97%5/8/2025 (Estimated)
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$81.17M-$9.39N/AN/AN/AN/A-50.25%-38.48%5/13/2025 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$98.92M-$2.31N/AN/AN/A-8,043.28%-71.31%-56.85%5/14/2025 (Estimated)
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$2.42M$0.4845.4310.310.451.75%25.35%6.21%5/6/2025 (Estimated)

Latest KRRO, PAHC, GYRE, and OCS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2025Q4 2024
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.33-$2.26+$0.07-$2.26N/A$2.27 million
3/17/2025Q4 2024
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.04$0.01-$0.03$0.02$23.50 million$27.87 million
3/11/2025Q4 2024
Oculis Holding AG stock logo
OCS
Oculis
-$0.48-$0.76-$0.28-$0.76$0.21 millionN/A
2/5/2025Q2 2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.40$0.54+$0.14$0.08$292.26 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/AN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.482.22%N/A100.00%N/A

Latest KRRO, PAHC, GYRE, and OCS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/4/2025
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
quarterly$0.122.18%3/5/20253/5/20253/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/A
3.72
3.29
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/A
11.23
11.23
Oculis Holding AG stock logo
OCS
Oculis
0.01
4.02
4.02
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.99
3.20
1.37

Institutional Ownership

CompanyInstitutional Ownership
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
23.99%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
13.18%
Oculis Holding AG stock logo
OCS
Oculis
22.30%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%

Insider Ownership

CompanyInsider Ownership
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
19.52%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
5.40%
Oculis Holding AG stock logo
OCS
Oculis
N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
50.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
4093.61 million75.27 millionNo Data
Korro Bio, Inc. stock logo
KRRO
Korro Bio
709.39 million8.86 millionNo Data
Oculis Holding AG stock logo
OCS
Oculis
243.66 millionN/ANot Optionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,86040.50 million20.22 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gyre Therapeutics stock logo

Gyre Therapeutics NASDAQ:GYRE

$8.90 -0.19 (-2.13%)
As of 10:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Korro Bio stock logo

Korro Bio NASDAQ:KRRO

$17.85 -0.53 (-2.88%)
As of 10:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Oculis stock logo

Oculis NASDAQ:OCS

$19.51 +0.11 (+0.59%)
As of 10:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$21.66 -0.02 (-0.11%)
As of 10:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.